New hope for lung cancer patients whose targeted therapy stops working
NCT ID NCT05870319
First seen Nov 17, 2025 · Last updated Jun 18, 2026 · Updated 29 times
Summary
This study tests a new drug called SKB264 against standard chemotherapy in people with advanced non-squamous non-small cell lung cancer that has a specific EGFR mutation and has stopped responding to targeted therapy (EGFR-TKI). About 376 participants will be randomly assigned to receive either SKB264 alone or a chemo combination. The main goal is to see if SKB264 can delay cancer growth better than chemo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510060, China
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.